Danish drugmaker Novo Nordisk has added its name to the list of insulin producers cutting prices for US retail buyers, following up on Eli Lilly’s announcement of price...
Bayer is looking to spend $1 billion on drug research and development in the United States during 2023 as part of a plan to double its sales in the country by the end of...
As the discussion surrounding the high price of insulin in the US continues unabated, drugmaker Eli Lilly implemented price reductions of 70% for its most commonly...
Danish pharma Novo Nordisk is expanding its R&D capabilities in Boston, Massachusetts, US, which will lead to the closure of a facility in Indianapolis and a...
The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate...
Denmark’s Novo Nordisk has entered into a global license and development with compatriot biotech Zealand Pharma for the latter’s Zegalogue (dasiglucagon) injectable...
Danish pharma Novo Nordisk has agreed to acquire US clinical-stage biopharma Forma Therapeutics in a deal worth $1.1 billion that will expand its blood disorders...
